Press Releases
<< Back
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
-- Study highlights need to address varying levels of effective disease management, and the associated feelings of uncertainty, stress and isolation across eight European countries –
-- Country-specific data show German respondents experience highest levels of anxiety, more than half of
Peanut allergy is one of the most common food allergies, which affect over 17 million people in
APPEAL-1 is the first and largest quantitative study to validate and bring attention to the significant burden and psychosocial impact with which allergic individuals and their caregivers are challenged in their daily lives. The findings illustrate the impact of living with the condition, and how attempting to avoid peanuts every day can be a major source of stress, fear and anxiety, clouded by the persistent worry of accidental exposure for both the allergic individual and their caregiver. The data also demonstrate that across
“Our findings show that those living with peanut allergy face many uncertainties and restrictions on their daily activities, in addition to constant feelings of frustration, anxiety, stress, isolation, and uncertainty in their everyday lives,” said Audrey DunnGalvin, Ph.D., a lead investigator on the APPEAL-1 study and a lecturer in the
The APPEAL-1 Part A data provide meaningful insights into the experience of those with peanut allergy related to their reactions and disease management. Of the 1,300 survey participants:
- 45% rate their worst allergy reactions as severe, and 31% require the use of rescue medicine (adrenaline auto-injector; AAI) and hospitalization for their worst reaction. Of this latter group, percentages are higher in younger age groups; 35% in children and 42% in teenagers, compared with 26% in adults.
- Despite this, more than a quarter had never been prescribed an adrenaline auto-injector (AAI), and only 24% of all respondents received training on what to do in an emergency. Of those that had been prescribed an AAI, only a third had received training on how to use it.
- 87.4% report multiple symptoms during their worst allergic reactions, the most common symptoms included swelling (lips, eyes, tongue), breathing difficulties/wheezing and itching mouth or throat tightness. Almost one third report gastrointestinal symptoms (vomiting 30%, nausea 27%, stomach pain/cramps 24%).
- Comorbidities are common, with 42%, 50% and 79% reporting comorbid allergic rhinitis, asthma, and other food allergy, respectively.
- Nearly half of all respondents (n=1,846) (46%) describe living with the disease as “more” or “much more” expensive than living without the disease, pointing to a financial burden associated with managing peanut allergy. Most respondents note “significant” indirect costs associated with the extra time needed for planning day-to-day activities (85%) and special events (91%).
The APPEAL-1 Part B data show the impact on individuals’ freedom of choice in daily activities; feelings and emotions; impacts of bullying, and their ability to cope with peanut allergy. Of the 1,846 survey respondents:
- 90% report feeling frustrated and stressed, with over a third having frequent feelings of anxiety.
- 65% report feelings of isolation and 43% report experiencing bullying.
- 89% report feeling restricted on where to eat out and 84% feel limited on buying food.
- Moreover, respondents report limitations in other areas of their lives not related to food, such as choice of schools (55%), socializing (75%) and going to special occasions (89%). More than half (54%) even worry about exposure during social occasions where food is not involved.
Within these data, there are some cross-country differences observed:
- In
- In
- More than half (52%) of respondents in the
- Confidence in recognizing allergic reaction symptoms and on how and when to use rescue medicine was dangerously low in
“The study provides essential insight and data on peanut allergy comorbidities, severity of reactions, management, and suggests a widespread need in
Aimmune has a Marketing Authorization Application (MAA) under review with the
About the APPEAL-1 Study
APPEAL-1 (Allergy to Peanuts ImPacting Emotions And Life-1) collected data from 1,846 respondents (allergic individuals and their caregivers) across eight European countries and is the first pan-European quantitative, cross-sectional survey that explored the psychosocial impacts of living with peanut allergy with use of a novel questionnaire. The three respondent groups included 528 self-reporting adults with peanut allergy; 881 self-reporting caregivers, and 437 children with peanut allergy reported by proxy of their caregiver (of these children, 34 were aged 0-3 years, 287 aged 4-12 years, 116 aged 13-17 years).
About Peanut Allergy
Peanut allergy is one of the most common food allergies, which affects over 17 million people in
About
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding potential applications of the CODIT approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the risk that the COVID-19 worldwide pandemic may continue to negatively impact the business, research and clinical operations of Aimmune or its partners; Aimmune’s or any of its collaborative partners’ ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s or any of its collaborative partners’ clinical trials will not be successful; Aimmune’s dependence on the success of commercialization; Aimmune’s reliance on third parties for the manufacture of Aimmune’s products and product candidates; possible regulatory developments in
AIMMUNE™, AIMMUNE THERAPEUTICS™ and CODIT™ are trademarks of
References
i EAACI. Food Allergy & Anaphylaxis Public Declaration, 2015. http://www.eaaci.org/attachments/FoodAllergy&AnaphylaxisPublicDeclarationCombined.pdf
ii EAACI. Food Allergy & Anaphylaxis Public Declaration, 2015. http://www.eaaciorg/attachments/FoodAllergy&AnaphylaxisPublicDeclarationCombined.pdf
iii Du Toit G, et al. N Engl J Med 2015; 372: 803-13
iv
v EAACI. Food Allergy & Anaphylaxis Public Declaration, 2015. http://www.eaaci.org/attachments/FoodAllergy&AnaphylaxisPublicDeclarationCombined.pdf
vi EAACI. Food Allergy & Anaphylaxis Public Declaration, 2015. http://www.eaaci.org/attachments/FoodAllergy&AnaphylaxisPublicDeclarationCombined.pdf
vii Du Toit G, et al. N Engl J Med 2015; 372: 803-13
viii
ix Crespo JF, James JM,
x Moreno MA. Guidelines for children with peanut allergy. JAMA Pediatr. 2017;171:100.
xi Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. J Allergy Clin Immunol. 2001;107:367-74.
xii Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. The natural progression of peanut allergy: resolution and the possibility of recurrence. J Allergy Clin Immunol. 2003;112:183-9.
xiii Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol. 2016;16:751-65.
xiv Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in
xv Sampson HA, Aceves S,
xvi Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014;69:1008-25.
xvii Rimbaud L, Heraud F, La Vieille S, Leblanc J-C, Crépet A. Quantitative risk assessment relating to the inadvertent presence of peanut allergens in various food product. Int Food Risk Anal J. 2013;3:1-11.
xviii Allen KJ, Remington BC, Baumert JL, et al. Allergen reference doses for precautionary labeling (VITAL 2.0): clinical implications. J Allergy Clin Immunol. 2014;133:156-64.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005252/en/
Investors:
(917) 834-1494
dsheel@aimmune.com
Media:
+44 7747-477509
lstrong@w2ogroup.com
Source: